1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • September 2014
  • 323 pages
  • GlobalData
Report ID: 2568516

Summary

Table of Contents

Search Inside

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

Summary

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Since its introduction in 1998, Roche’s gold standard therapy, Herceptin (trastuzumab), a monoclonal antibody, revolutionized the treatment of the disease. The realization that targeting the HER2 receptor could significantly improve disease-free survival (DFS) has created a large market for HER2-directed therapies. In 2013, Roche dominated the HER2-positive market, with a share of 95%. With Herceptin’s patent expiry looming in Europe Roche launched Perjeta and Kadcyla in 2012 and 2013 to maintain its leadership. GlobalData forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023.

The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche’s targeted therapies. The HER2-positive pipeline is weak, and there are still unmet needs that have yet to be suitably addressed. GlobalData expects that the HER2-positive market will grow due to the premium pricing of new agents, and an increasing aging population in the US, 5EU, Japan, and China.

Key Questions Answered

- What are the R&D strategies being used by drug makers?
- How is the disease management evolving? What impact for drug manufacturers?
- What opportunities remain for future players?
- How large are the neoadjuvant, adjuvant, and metastatic markets for HER2 targeting agents, and which one is growing the fastest?
- What exciting, innovative approaches are being investigated in HER2-positive breast cancer?
- What to KOLs think about the latest therapies and drug development strategies?

Key Findings

- The HER2-positive breast cancer market will increase by 2.5-fold, reaching $12.63bn by 2023, at a CAGR of 9.82%, driven by the rapid uptake of the latest premium-priced biologics. Approval of these agents in the early (non-metastatic) stages will have the greatest impact on the market, along with combinations of branded therapies.
- By 2023, the largest market segment will be the adjuvant setting, with rapid growth at a CAGR of 12.3%, and representing 63% of the total HER2-positive market. Herceptin will no longer be the market leader, with new agents Perjeta and Kadcyla taking 37% and 39% market share respectively.
- The patent expiry of Herceptin in the 5EU in 2014, and in the US in 2019, will significantly reduce Herceptin sales, however, its introduction of a more convenient subcutaneous reformulation of Herceptin will limit this impact.
- Development of new HER2-targeting therapies is slow, with only one agent, Puma Biotechnology’s neratinib, in Phase III, following the failure of BI’s gilotrif. The recent failure of GSK’s Tykerb in the adjuvant setting shows that TKIs are best suited to later stages of metastatic disease.
- Entry into the Roche-dominated HER2-positive market is challenging, with new players needing to find alternative MOAs in underserved patient populations. KOLs identified areas of important unmet need that can still provide opportunities in the HER2-positive space.
- Future drug development will begin to merge the HER2-positive and HER2-negative populations, as new targets and MOAs are developed, providing exciting opportunities.

Scope

- Overview of HER2-positive breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HER2-positive breast cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in six patient segments (including neoadjuvant and adjuvant), forecast from 2013 to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HER2-positive breast cancer therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global HER2-positive breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-positive breast cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Epiomic Epidemiology Series: BRCA 1 & 2 Mutation in Cancer Forecast in 18 Major Markets 2017-2027

  • $ 6859
  • Industry report
  • June 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major Markets It has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility ...

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

  • $ 4995
  • Industry report
  • April 2017
  • by GBI Research

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market Summary Breast cancer is a malignant neoplasm that begins ...

Histology and Cytology Market Analysis By Type of Examination (Cytology [Cervical Cancer, Breast Cancer, Others], Histology), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global histology and cytology market size is expected to reach USD 26.9 billion by 2025, according to a new report by Grand View Research, Inc. Globally, the increasing incidence of cancer and growing ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.